SEC FORM 3

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Shook David

(Last)

(First)

(Middle)

C/O NKARTA, INC.

6000 SHORELINE COURT, SUITE 102

(Street)

SOUTH SAN FRANCISCO

94080

(City)

(State)

(Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
01/01/2023

3. Issuer Name and Ticker or Trading Symbol
Nkarta, Inc. [ NKTX ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Medical Officer

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	22,977⁽¹⁾	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
Stock Option (right to buy)	⁽²⁾	07/08/2030	Common Stock	13,300	$18	D
Stock Option (right to buy)	⁽³⁾	07/08/2030	Common Stock	4,300	$18	D
Stock Option (right to buy)	⁽⁴⁾	07/08/2030	Common Stock	4,800	$18	D
Stock Option (right to buy)	⁽⁵⁾	01/07/2031	Common Stock	4,680	$54.89	D
Stock Option (right to buy)	⁽⁶⁾	04/29/2031	Common Stock	150	$31.85	D
Stock Option (right to buy)	⁽⁷⁾	01/13/2032	Common Stock	3,310	$12.14	D
Stock Option (right to buy)	⁽⁸⁾	04/28/2032	Common Stock	5,000	$18.44	D
Stock Option (right to buy)	⁽⁹⁾	05/15/2032	Common Stock	7,000	$13.86	D
Stock Option (right to buy)	⁽¹⁰⁾	06/16/2032	Common Stock	35,000	$12.25	D
Stock Option (right to buy)	⁽¹¹⁾	08/19/2032	Common Stock	30,000	$16.46	D

Explanation of Responses:

1. Includes 1,660 Restricted Stock Units ("RSUs") which vest in four equal annual installments beginning on January 14, 2023, 5,000 RSUs which vest in four equal annual installments beginning on June 17, 2023, and 15,000 RSUs which vest in four equal annual installments beginning on August 20, 2023. Each RSU represents a contingent right to receive one share of Common Stock of the Issuer.

2. The option is vested and exercisable as to 8,589 shares, and the remaining shares will vest and become exercisable ratably in monthly installments until fully vested on June 1, 2024.

3. The option is vested and exercisable as to 2,687 shares, and the remaining shares will vest and become exercisable ratably in monthly installments until fully vested on July 1, 2024.

4. The option is vested and exercisable as to 3,000 shares, and the remaining shares will vest and become exercisable ratably in monthly installments until fully vested on July 9, 2024.

5. The option is vested and exercisable as to 2,340 shares, and the remaining shares will vest and become exercisable ratably in monthly installments until fully vested on January 8, 2025.

6. The option is vested and exercisable as to 62 shares, and the remaining shares will vest and become exercisable ratably in monthly installments until fully vested on April 30, 2025.

7. The option is vested and exercisable as to 759 shares, and the remaining shares will vest and become exercisable ratably in monthly installments until fully vested on January 14, 2026.

8. The option is vested and exercisable as to 833 shares, and the remaining shares will vest and become exercisable ratably in monthly installments until fully vested on April 29, 2026.

9. The option is vested and exercisable as to 1,021 shares, and the remaining shares will vest and become exercisable ratably in monthly installments until fully vested on May 16, 2026.

10. The option is vested and exercisable as to 4,375 shares, and the remaining shares will vest and become exercisable ratably in monthly installments until fully vested on June 17, 2026.

11. The option is vested and exercisable as to 2,500 shares, and the remaining shares will vest and become exercisable ratably in monthly installments until fully vested on August 20, 2026.

Remarks:

	/s/ Alicia Hager, as Attorney-in-Fact	01/10/2023
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.